Toripalimab and Anlotinib
Sponsors
Sun Yat-sen University, Qilu Hospital of Shandong University
Conditions
Locally Advanced or Metastatic Acral Malignant MelanomaNasopharyngeal CarcinomaRecurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
CompletedNCT04996758
Start: 2021-10-30End: 2024-12-01Updated: 2024-12-12
Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma
NCT05087602
Start: 2021-11-01End: 2023-10-30Target: 29Updated: 2021-10-21